<DOC>
	<DOCNO>NCT00358982</DOCNO>
	<brief_summary>MGCD0103 experimental drug belongs class drug know histone deacetylase inhibitor , may restore normal control cancer cell affect gene protein make . Laboratory test show new investigational anti-cancer drug slow growth human cancer cell mice ; two clinical research study currently perform human cancer similar study perform patient disease . The purpose study find effect experimental drug MGCD0103 patient relapse refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Study MGCD0103 ( MG-0103 ) Patients With Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Pathologic confirmation relapse refractory classical Hodgkin 's lymphoma . The patient least one site measurable disease ( ≥ 2.0 cm ) measure conventional technique CT MRI . Prior treatment : limit number prior therapy . Patients prior allogeneic stem cell transplant evidence graft versus host disease receive immunosuppressive agent eligible meet inclusion criterion . ECOG performance status 0 1 . Aged 18 year old ( safety data yet age &lt; 18 ) . Laboratory requirement ( must do within 7 day prior study initiation ) . Patients another active cancer ( exclude basal cell carcinoma cervical intraepithelial neoplasia [ CIN/cervical situ ] melanoma situ ) . Prior history cancer allow , long active disease . Pregnant lactating woman . Women childbearing potential ( WOCBP ) must negative serum pregnancy test document within 7 day prior start study drug . WOCBP men whose partner WOCBP must use acceptable method contraception enrol study , period 3 month follow study drug treatment . Patients uncontrolled intercurrent illness , active uncontrolled infection , fever &gt; 38.5°C ( due tumor fever ) day schedule dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Relapsed Refractory Hodgkin 's Lymphoma</keyword>
	<keyword>Phase II</keyword>
</DOC>